Cencora (COR) to Release Quarterly Earnings on Wednesday

Cencora (NYSE:COR) will be issuing its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $3.65 per share for the quarter. Cencora has set its FY 2024 guidance at 13.250-13.500 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $3.28 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.42. Cencora had a net margin of 0.69% and a return on equity of 323.23%. The company had revenue of $72.25 billion during the quarter, compared to analysts’ expectations of $68.81 billion. During the same period last year, the business earned $2.71 EPS. On average, analysts expect Cencora to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Cencora Price Performance

NYSE:COR opened at $237.73 on Wednesday. Cencora has a 1-year low of $163.37 and a 1-year high of $246.75. The company has a current ratio of 0.88, a quick ratio of 0.52 and a debt-to-equity ratio of 3.94. The firm has a fifty day simple moving average of $238.11 and a 200 day simple moving average of $216.73. The stock has a market capitalization of $47.42 billion, a PE ratio of 25.90, a P/E/G ratio of 1.83 and a beta of 0.45.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 26th. Investors of record on Friday, February 9th were paid a $0.51 dividend. The ex-dividend date of this dividend was Thursday, February 8th. This is a boost from Cencora’s previous quarterly dividend of $0.24. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is currently 22.22%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 6,977 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the completion of the sale, the executive vice president now owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,212,395 shares of Cencora stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $235.41, for a total transaction of $991,639,906.95. Following the completion of the sale, the insider now owns 26,277,561 shares of the company’s stock, valued at $6,186,000,635.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth S. Campbell sold 6,977 shares of Cencora stock in a transaction on Monday, March 18th. The stock was sold at an average price of $238.12, for a total value of $1,661,363.24. Following the sale, the executive vice president now directly owns 8,246 shares of the company’s stock, valued at approximately $1,963,537.52. The disclosure for this sale can be found here. Insiders sold 4,288,790 shares of company stock valued at $1,009,641,379 in the last quarter. 15.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. SVB Leerink assumed coverage on shares of Cencora in a research note on Monday, February 26th. They issued an “outperform” rating and a $261.00 target price for the company. Mizuho raised their target price on shares of Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Barclays began coverage on shares of Cencora in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 target price for the company. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Cencora in a report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $218.22.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.